Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind active-controlled trial of HYR-PB21 injection for pain control after unilateral total knee arthroplasty
CTR20241330Phase 2Active
- Sponsor
- Hefei Cosource Pharmaceutical
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HYR-PB21 in postoperative pain, sponsored by Hefei Cosource Pharmaceutical. Started Jun 2024; status: active.
02
Drugs
HYR-PB21
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20241330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241330.